Myriad GeneticsSTU:MYD +4.86%49 OCF Yield % is 0.42 as of Jul. 02, 2026, which is 25% below its 10-year median of 0.56. GuruFocus rates STU:MYD with a GF Score™ of 49/100 and a GF Value™ of €13.14 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Myriad Genetics ranks worse than 53.27% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Myriad Genetics's OCF Yield % or its related term are showing as below:
STU:MYD'
s OCF Yield % Range Over the Past 10 Years
Min: -9.68 Med: 0.56 Max: 11.78
Current: 0.42
During the past 13 years, the highest OCF Yield % of Myriad Genetics was 11.78%. The lowest was -9.68%. And the median was 0.56%.
STU:MYD's OCF Yield % is ranked worse than 53.27% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.02
vs STU:MYD: 0.42
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Myriad Genetics OCF Yield % Related Terms
Myriad Genetics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MYD vs FLGT, CSTL, BDSX: OCF Yield % Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (STU:MYD) has a OCF Yield % of 0.42 as of Jul. 02, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Myriad Genetics and its competitors. This is 25% below median its historical median of 0.56. According to the industry distribution chart, Myriad Genetics ranks #114 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 53.3%.
Is Myriad Genetics' OCF Yield % too high?
Myriad Genetics' current OCF Yield % of 0.42 is 25% below median its 10-year median of 0.56. The Medical Diagnostics & Research industry median OCF Yield % is 1.02. Myriad Genetics' value of 0.42 is 58.8% below this industry median. Based on the distribution chart, Myriad Genetics ranks #114 out of 214 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Myriad Genetics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' OCF Yield % compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #114 out of 214 companies for OCF Yield %. This places Myriad Genetics in the lower half of its industry. The industry median OCF Yield % is 1.02. Myriad Genetics' value of 0.42 is 58.8% below this benchmark. While the company's 10-year median is 0.56 vs. the industry median of 1.02, Myriad Genetics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.02, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myriad Genetics's current OCF Yield % of 0.42 is 58.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current OCF Yield % is 0.42, which is 25% below median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.14, compared to a current price of €5.20 — trading 60.4% below its estimated fair value. The current OCF Yield % is 0.42, which is 25% below median its 10-year median of 0.56 and 58.8% below the Medical Diagnostics & Research industry median of 1.02. Myriad Genetics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current OCF Yield % is 0.42 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €5.20 is trading 60.4% below its estimated GF Value™ of €13.14.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
OCF Yield %: 0.42 (25% below median its 10-year median of 0.56)
GF Value™: €13.14 vs. price of €5.20 (60.4% below fair value)
Industry Position: 58.8% below the Medical Diagnostics & Research median (#114 of 214)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
49GF Score
Get the complete analysis for STU:MYD
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
